West Pharmaceutical Services Q4 Forecast: $793.4M Revenue, $1.83 EPS
West Pharmaceutical Services generated $804.6M in Q3 revenue (+7.7% YoY, 2.1% beat), while analysts forecast Q4 revenue of $793.4M (+6% YoY) and adjusted EPS of $1.83. The stock, down 10.8% over the last month, trades against a $333.57 average analyst target.
1. Past Quarter Performance
West recorded Q3 revenue of $804.6 million, up 7.7% year-on-year and 2.1% ahead of consensus, while adjusted EPS also exceeded full-year guidance projections. Strong demand for its drug delivery components underpinned the solid quarter.
2. Q4 Guidance and Analyst Estimates
Analysts project Q4 revenue of $793.4 million, representing 6% year-on-year growth, and adjusted EPS of $1.83 per share. Estimate revisions have been minimal over the past month, indicating aligned expectations for the upcoming report.
3. Peer Comparisons and Market Reaction
In the drug development services segment, Medpace reported 32% revenue growth and IQVIA posted 10.3%, both topping estimates, yet their shares fell 16.1% and 7.4% respectively. These declines highlight market sensitivity despite outperformance.
4. Stock Performance and Valuation
West’s shares have declined 10.8% over the past month versus a 3.7% drop for peers, reflecting broader sector weakness. At a current price below the $333.57 average analyst target, the stock implies meaningful upside potential.